These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8908676)

  • 1. Morphometry of benign prostatic hyperplasia during androgen suppressive therapy. Relationships among epithelial content, PSA density, and clinical outcome.
    Svindland A; Eri LM; Tveter KJ
    Scand J Urol Nephrol Suppl; 1996; 179():113-7. PubMed ID: 8908676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can prostate epithelial content predict response to hormonal treatment of patients with benign prostatic hyperplasia?
    Eri LM; Svindland A
    Urology; 2000 Aug; 56(2):261-5. PubMed ID: 10925090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of bicalutamide and leuprolide on prostate-specific antigen (PSA), acid phosphatase (ACP) and prostatic acid phosphatase (PAP) in men with benign prostatic hyperplasia (BPH).
    Eri LM; Tveter KJ
    Prostate Cancer Prostatic Dis; 2001; 4(3):173-177. PubMed ID: 12497037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
    Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
    J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia.
    Oesterling JE
    J Androl; 1991; 12(6):381-8. PubMed ID: 1722794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
    Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
    Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia.
    Türkeri LN; Ozyürek M; Ersev D; Akdaş A
    Arch Esp Urol; 2001 Mar; 54(2):191-6. PubMed ID: 11341128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between morphometric differences and norepinephrine content in benign prostatic hyperplasia.
    Ishigooka M; Hashimoto T; Hayami S; Suzuki Y; Sasagawa I; Nakada T
    Prostate; 1996 Jun; 28(6):385-91. PubMed ID: 8650076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
    Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative effects of transurethral incision (TUIP) and the combination of TUIP and LHRH agonists in the treatment of benign prostatic hypertrophy].
    Di Silverio F; D'Eramo G; Flammia GP; De Vico A; Casale P; Sciarra A
    J Urol (Paris); 1996; 102(3):111-6. PubMed ID: 9091555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F
    Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative and total volume of histological components in benign prostatic hyperplasia: relationships between histological components and clinical findings.
    Ishigooka M; Hayami S; Hashimoto T; Suzuki Y; Katoh T; Nakada T
    Prostate; 1996 Aug; 29(2):77-82. PubMed ID: 8700803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.
    Colli E; Rigatti P; Montorsi F; Artibani W; Petta S; Mondaini N; Scarpa R; Usai P; Olivieri L; Maggi M;
    Eur Urol; 2006 Jan; 49(1):82-6. PubMed ID: 16310924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of contact laser versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia with small or moderately enlarged prostates.
    Tuhkanen K; Heino A; Aaltomaa S; Ala-Opas M
    Scand J Urol Nephrol; 2003; 37(6):487-93. PubMed ID: 14675922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.